BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

BioAge Labs, Inc.NASDAQ: BIOA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $20.41M rose 83.7% year over year, ahead of the +36.9% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.

Context

  • Research & development amounted to 822.3% of revenue in FY2025.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +83.7% holds above the trailing-twelve-month pace of +36.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.41M-16.7% QoQ
Last fiscal yearDec 2025
$73.97M+25.3% YoY
LTMMar 2026
$83.27M+36.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.7%——
1 year+25.3%——
3-year CAGR+34.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
73.97M USD
Year-over-year change
+25.3%
3-year CAGR
+34.3%

Research & Development vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.9% is the 3rd highest of 9, against a peer median of -9.7%.
  • Research & development amounts to 807.2% of revenue for BIOA, versus a peer median of 5.5%.
BIOA Competitors
Research & Development for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M USD+37.4%+18.6%—
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M USD+44.8%+53.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
HUMAHumacyte, Inc.LTM Mar 2026$73.35M USD-11.4%+3.1%3638.2%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$7.58M USD—+1.8%5.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.98M CAD+35.4%+1.4%1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.25M USD-8.0%-34.3%5.4%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD-100.0%—0.0%
Peer median (excluding BIOA) —-9.7%+1.6%5.5%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.